share_log

JP Morgan Reinstates Overweight on BioCryst Pharma, Announces $10 Price Target

JP Morgan Reinstates Overweight on BioCryst Pharma, Announces $10 Price Target

摩根大通恢复对BioCryst Pharma的增持,宣布10美元的目标股价
Benzinga ·  2023/11/20 08:15

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Overweight and announces $10 price target.

摩根大通分析师杰西卡·费伊宣布增持BioCryst Pharma(纳斯达克股票代码:BCRX),并宣布目标股价为10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发